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Purpose: Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors activated by ligands of the nuclear hormone 
receptor superfamily. The activation of PPARg regulates inflammation by downregulating the production of Th2 type cytokines and eosinophil 
function. In addition, a range of natural substances, including arachidonate pathway metabolites such as 15-hydroxyeicosatetranoic acid (15-
HETE), strongly promote PPARG expression. Therefore, genetic variants of the PPARG gene may be associated with the development of aspirin-
intolerant asthma (AIA). We investigated the relationship between single nucleotide polymorphism (SNP) of the PPARG gene and AIA. Methods: 
Based on the results of an oral aspirin challenge, asthmatics (n=403) were categorized into two groups: those with a decrease in FEV1 of 15% 
or greater (AIA) or less than 15% (aspirin-tolerant asthma, ATA). We genotyped two single nucleotide polymorphisms in the PPARG gene from 
Korean asthmatics and normal controls (n=449): +34C>G (Pro12Ala) and +82466C>T (His449His). Results: Logistic regression analysis showed 
that +82466C>T and haplotype 1 (CC) were associated with the development of aspirin hypersensitivity in asthmatics (P=0.04). The frequency of 
the rare allele of +82466C>T was significantly higher in AIA patients than in ATA patients in the recessive model [P=0.04, OR=3.97 (1.08–14.53)]. 
In addition, the frequency of PPARG haplotype 1 was significantly lower in AIA patients than in ATA patients in the dominant model (OR=0.25, P= 
0.04). Conclusions: The +82466C>T polymorphism and haplotype 1 of the PPARG gene may be linked to increased risk for aspirin hypersensitivity 
in asthma.
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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are tran-
scriptional factors activated by ligands of the nuclear hormone 
receptor superfamily. This superfamily is divided into the ste-
roid receptor family and the thyroid, vitamin D, and retinoid (or 
non-steroid) receptor family.
1 Three different PPAR subtypes 
have been identified: PPARa (PPARA), PPARg (PPARG), and 
PPARd (PPARD, which is also called PPARb). PPARG (MIM 
#601487), located on chromosome 3p25, plays an important 
role in regulating adipocyte differentiation and lipid metabo-
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lism
2 as well as cell turnover.
3 However, the production of im-
mune-modulating cytokines in various cell types was reported 
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to downregulate the expression of PPARG, and block adipocyte 
differentiation. It is well established that a variety of natural 
substances, including arachidonate pathway metabolites such 
as 15-hydroxyeicosatetranoic acid (15-HETE), strongly pro-
mote PPARG expression.
3-5 Stimulation of the PPARG ligand 
significantly inhibited the downregulation of eosinophil func-
tion.
6 PPARG expression is associated with the inflammatory 
and remodeling responses in the asthmatic airway.
7
Among the sub-phenotypes of asthma, aspirin-intolerant 
asthma (AIA) refers to the development of bronchoconstriction 
in asthmatic individuals following the ingestion of aspirin or 
other non-steroidal anti-inflammatory drugs. This syndrome is 
characterized by the ‘aspirin triad’ of aspirin hypersensitivity, 
bronchial asthma, and nasal polyposis.
8 Most clinical investiga-
tors now include chronic hyperplastic eosinophilic sinusitis 
(CHES) as a fourth hallmark of aspirin-exacerbated respiratory 
disease (AERD).
9 As is true for other asthmatic individuals, the 
airways of patients with AIA show signs of persistent inflamma-
tion, with marked eosinophilia, epithelial disruption, cytokine 
production, and upregulation of inflammatory molecules.
10 Al-
though the pathogenesis of AIA has not been elucidated com-
pletely, multiple points of overproduction or underproduction 
of critical mediators in the metabolism of arachidonic acid, in-
cluding leukotrienes, lipoxins, thromboxane, and prostaglan-
dins, probably account for the susceptibility to aspirin.
10 In ad-
dition, the levels of proinflammatory, immune cytokines and 
chemokines, including IL-2, IL-3, IL-4, IL-5, IL-13, GM-CSF, 
and eotaxin, are increased in the airways and systemic circula-
tion in AIA.
11,12 The production of these molecules is regulated 
by various transcription factors, including PPARG. Therefore, 
genetic variants of the PPARG gene may be associated with the 
development of asthma or aspirin intolerance in asthmatics.
Recently, Palmer et al.
13 reported that PPARG gene polymor-
phisms are associated with a risk for asthma exacerbation in 
Caucasian populations. We also reported that the homozygous 
haplotype combination of +34C>G (Pro12Ala) was associated 
with an increased risk for asthma exacerbation.
13 To our knowl-
edge, however, no study has analyzed the potential associations 
of the two common polymorphisms of the PPARG gene [+34C>G 
(Pro12Ala) and +82466C>T (His449His)] with the risk for aspi-
rin intolerance in asthmatics.
 
MATERIALS AND METHODS
Subjects
The subjects were recruited from the Asthma Genome Re-
search Center, comprising Soonchunhyang Bucheon, Seoul, 
and Chunan Hospitals, and Chunnam and Chungbuk Univer-
sity Hospitals in Korea. All of the subjects were Korean. A clini-
cal history was obtained for each patient, using a physician-ad-
ministered questionnaire that included the history of aspirin 
hypersensitivity. The asthmatics had compatible clinical symp-
toms and physical characteristics (Global Initiative for Asth-
ma).
14 All patients had a history of dyspnea and wheezing dur-
ing the previous 12 months plus one of the following: 1) >15% 
increase in FEV1 or >12% increase plus 200 mL following inha-
lation of a short-acting bronchodilator; 2) <10 mg/mL PC20 
methacholine; or 3) >20% increase in FEV1 following 2 weeks of 
treatment with inhaled steroids and long-acting bronchodila-
tors. The asthmatics had experienced no exacerbation of asth-
ma or any respiratory tract infection in the 6 weeks preceding 
the oral aspirin challenge (OAC). Based on the results of the 
OAC, the asthmatics (n=403) were categorized into two groups: 
those with a decrease in FEV1 of 15% or greater (AIA, n=60), and 
those with a decrease of less than 15% [aspirin-tolerant asthma 
(ATA), n=343]. The oral provocation test was performed with 
increasing doses of aspirin (10-450 mg Astrix; Mayne Pharma, 
Melbourne, Australia) using a modification of a previously de-
scribed method.
15,16 Aspirin-intolerance bronchospasm, as re-
flected by the rate (%) of FEV1 decline, was calculated as the dif-
ference between the pre-challenge and post-challenge FEV1 
values divided by the pre-challenge FEV1. Subjects who devel-
oped skin manifestations were labeled as positive responders 
(n=60). Normal controls (n=449) were recruited from among 
spouses of the patients or members of the general population 
who answered negatively to a screening questionnaire regard-
ing respiratory symptoms.
17 The normal controls had no history 
of aspirin intolerance and had FEV1 values >80% predicted, 
PC20 methacholine >10 mg/mL, and normal findings on simple 
chest radiograms. Skin prick tests were performed with 24 com-
mon aeroallergens (Bencard, Brentford, UK). Atopy was de-
fined as one or more positive reactions (>3 mm in diameter) on 
the skin prick test. Total IgE was measured using a UniCAP sys-
tem (Pharmacia Diagnostics, Uppsala, Sweden). Subjects with 
diabetes mellitus were excluded because the PPARG polymor-
phism is reported to be associated with the development of dia-
betes mellitus in Koreans.
18 All subjects gave written informed 
consent to participate in the study, and the protocol was ap-
proved by the local ethics committees.
Genotyping the SNPs in the PPARG gene
The amplifying primers and probes used to genotype the 
polymorphic sites by the single base method were as described 
previously.
19 Primer Express (Applied Biosystems, Foster City, 
CA, USA) was used to design the PCR primers and MGB Taq-
Man probes. One allelic probe was labeled with FAM dye; and 
the other, with fluorescent VIC dye. PCR was performed in Taq-
Man Universal Master Mix, without uracil-N-glycosylase (Ap-
plied Biosystems), containing 900 nM TaqMan MGB-probe and 
200 nM primer. The reaction was performed in a 384-well plate 
in a total reaction volume of 5 µL, using 20 ng of genomic DNA. 
The plate was heated in a thermal cycler (PE 9700; Applied Bio-
systems) for 2 min at 50°C and then for 10 min at 95°C, followed 
by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The fluores-Allergy Asthma Immunol Res. 2009 October;1(1):30-35.  doi: 10.4168/aair.2009.1.1.30
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cence intensity of each reaction was determined using a Prism 
7900 HT detector (Applied Biosystems), and the fluorescence 
data were analyzed by automated software (SDS 2.1).
Statistical analysis
We applied the widely used Lewontin’s D’ (|D’|) and R
2 mea-
sures of linkage disequilibrium to all pairs of biallelic loci.
20 
Haplotype associations were estimated using HaploScore 
(http://www.biostat.wustl.edu/genetics/geneticssoft/), which 
computes score statistics to test for associations between a giv-
en haplotype and a wide variety of traits, including binary, ordi-
nal, quantitative, and Poisson parameters. The genetic effects of 
the haplotypes were analyzed in the same way as the SNPs. The 
distributions of the PPARG SNP genotypes and haplotypes 
among the subjects with asthma and the normal subjects were 
analyzed with logistic regression models that controlled for age 
(continuous value), gender (male=0, female=1), atopy status 
(non-atopy=0, atopy=1), body mass index (BMI; continuous 
value), and smoking status (nonsmoker=0, ex-smoker=1, 
smoker=2) as covariates. The data were managed and analyzed 
using SPSS ver. 10.0 (SPSS, Chicago, IL, USA). A value of P≤0.05 
was regarded as statistically significant.
RESULTS
Characteristics of the study subjects
We recruited 403 subjects from the asthma cohort. The clini-
cal characteristics of the study subjects are summarized in Ta-
ble 1. The maximum fall in FEV1 during the 5-hr follow-up peri-
od after aspirin challenge was used as the value for the aspirin-
induced fall in FEV1. Aspirin-induced declines in FEV1 ranged 
from -15% to 68%. The log transformed PC20 methacholine val-
ues for the asthmatics were significantly lower among those 
with AIA than among those with ATA (P=0.013, Table 1).
PPARG polymorphisms and the risk for aspirin intolerance in 
asthmatics
Two SNPs, +34C>G (P12A) on exon 3 and +82466C>T (H449H) 
on exon 8, in the PPARG gene were genotyped for the associa-
tion study. The minor allele frequencies (MAFs) of these two 
SNPs in the Korean population were 0.042 (+34C>G) and 0.168 
(+82466C>T) (Table 2). The genotype distributions of the two 
SNPs were in Hardy-Weinberg equilibrium for all subjects (P> 
0.05, Table 2). Four haplotypes were constructed, and two hap-
lotypes with a frequency >0.05 were used for the analysis. Using 
Table 1. The clinical profiles of the study subjects 
Description Normal controls ATA AIA P value
Number 449 343 60 -
Age (yr [range]) 44 (5-80)   48 (14-77)   45.5 (17-72)   0.375
Duration (yr [range]) -   3 (1-60)      5 (1-40)   0.383
Onset of age (yr [range]) - 41 (1-76) 38.5 (1-67)   0.186
Sex (Male, %) 40.31 33.53 35   0.824
Smoker (%) 17.16 13.12 10   0.127 
Atopy (%) 35.15 56.01 58.33   0.738
FVC (% predicted)   94.24±0.59 85.19±0.93 85.03±2.26 0.95
FEV1 (% predicted) 104.14±0.72 83.31±1.17 79.23±2.85   0.181
log (PC20 methacholine [mg/mL])       1.39±0.002   0.31±0.04 0.06±0.1   0.013
BMI (kg/m
2)   23.81±0.16 24.47±0.18 23.92±0.37   0.221
Blood eosinophil (%)   2.37±0.1     6.2±0.36   6.56±0.69 0.23
log transformed total IgE (IU/mL)     1.66±0.03   2.14±0.04   2.24±0.07   0.269
Rate of FEV1 decline after aspirin challenge (%) -   3.74±0.27 25.42±2.09   <0.0001
Values are mean±S.E. ATA and AIA represent aspirin-tolerant asthma and aspirin-intolerant asthma, respectively.
P values are obtained using T test or c2 test between AIA and ATA.
Table 2. The frequencies, heterozygosity and Hardy-Weinberg Equation of SNPs on PPARG gene in the study population
Loci rsSNP Region
Amino acid 
change
Genotype
Frequency Heterozygosity HWE
C/C C/R R/R N
+34C>G rs1801282 Exon4 Pro12Ala 784 65 3 852 0.042 0.076 0.192 
+82466C>T rs3856806 Exon10 His446His 594 230 28 852 0.168 0.270 0.327
C/C, C/R and C/C represent common allele, heterozygosity and rare allele.
*P values of deviation from Hardy-Weinberg Equilibrium (HWE) in the study population.Allergy Asthma Immunol Res. 2009 October;1(1):30-35.  doi: 10.4168/aair.2009.1.1.30
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multiple logistic regression models, both SNPs and the two 
haplotypes (ht1 and ht2) were analyzed for associations with 
the risk for aspirin intolerance in the asthmatics (Table 3). The 
analysis revealed that PPARG+82466C>T was associated with 
aspirin intolerance in the recessive model, and there were more 
subjects homozygous for the rare alleles PPARG+82466C>T in 
the AIA group than in the ATA group in the recessive model 
(6.66% vs 2.04%, P=0.04, OR=3.97 [1.08-14.53]). In the haplo-
type analysis, there were fewer subjects with ht1 in the AIA 
group than in the ATA group (93.33% vs 97.96%, P=0.04, OR= 
0.25 [0.07-0.92]) in the dominant model. The rate (%) of FEV1 
decline after aspirin challenge is the most important parameter 
for the diagnosis of aspirin intolerant asthmatics, and thus we 
used linear regression analysis to investigate the associations 
between the SNP (+82466C>T), haplotype 1, and percentage 
fall of FEV1 following aspirin challenge. Haplotype 1 and 
+82466C>T showed the strongest association with the rate (%) 
of FEV1 decline after aspirin challenge in the asthmatics. Asth-
matics homozygous for the rare +82466C>T allele had a greater 
decline in FEV1 after aspirin provocation than those with the 
common allele (P=0.0004, Fig. 1A). In the haplotype analysis, 
the decline in FEV1 after aspirin provocation was greater in 
asthmatics lacking the ht1 haplotype than in those with the 
haplotype (P=0.0004, Fig. 1B).
DISCUSSION
PPARs are receptors for steroids, thyroid hormone, vitamin D, 
and retinoic acid,
1 and they regulate adipocyte differentiation, 
lipid metabolism,
2 and cellular turnover.
3 Furthermore, poly-
morphisms of the PPARG gene have been associated with dia-
betes, obesity, and metabolic syndrome.
18,21-25 The two common 
polymorphisms of PPARG were reported to modify susceptibil-
ity to type II diabetes mellitus, obesity, and sub-phenotypes of 
metabolic syndrome in Koreans
18,21,22 and Caucasians.
23-26 
Therefore, we excluded subjects with diabetes from the analysis 
and adjusted the results for the BMI.
Table 3. Comparisons of genotype and haplotype distributions of PPARG between the subjects with AIA and those with ATA
Loci Position rsSNP
Geno-
type
N (%) Co-dominant Dominant Recessive
AIA ATA
OR
(95%CI)
P
value
OR
(95%CI)
P
value
OR
(95%CI)
P
value
+34C>G Exon4 rs1801282 C
CG
G
     55 (91.67%)
     
     4 (6.67%)
     1 (1.66%)
319 (93%)
24 (7%)
  0 (0%)
1.38
(0.55±3.44)
0.49  1.14
(0.41±3.14)
0.8 - -
+82466C>T Exon10 rs3856806 C
CT
T
     46 (76.67%)
     
     10 (16.67%)
     4 (6.66%)
     250 (72.89%)
      
       86 (25.07%)
       7 (2.04%)
1.02
(0.59±1.75)
0.95 0.79
(0.41±1.51)
0.47 3.97
(1.08±14.53)
0.04 
ht1 - - -/-
ht1/-
ht1/ht1
     4 (6.67%)
12 (20%)
     44 (73.33%)
       7 (2.04%)
    
       88 (25.66%)
   248 (72.3%)
0.89
(0.52±1.5)
0.65 0.25
(0.07±0.92)
0.04 1.09
(0.58±2.04)
0.79 
ht2 - - -/-
ht2/-
ht2/ht2
48 (80%)
    
     10 (16.67%)
     2 (3.33%)
     269 (78.43%)
   
       70 (20.41%)
       4 (1.16%)
1.03
(0.56±1.89)
0.93 0.9
(0.45±1.78)
0.75 3.48
(0.6±20.18)
0.16 
ATA and AIA represent aspirin-tolerant asthma and aspirin-intolerant asthma, respectively. C/C, C/R and R/R represent common allele, heterozygosity and 
rare allele. The P values were obtained by logistic regression analysis, controlled for age (continuous value), sex (male=0, female=1), atopy status (non-atopy=0, 
atopy= 1) and smoking status (non-smoker=0, ex-smoker=1, smoker=2) and BMI (continuous value) as co-variables.
Bold faces mean the P<0.05.
Fig. 1. The comparison of the rate of fall (%) of FEV1 with aspirin provoca-
tion between subjects possessing the rare and common alleles by (A) 
+82466C>T and (B) haplotype 1 of PPARG gene. The P values were obtained 
by linear regression analysis, controlled for age (continuous value), gender 
(male=0, female=1), atopy status (non-atopy=0, atopy=1), smoking status 
(non-smoker=0, ex-smoker=1, smoker=2), and BMI (continuous value) as co-
variates.
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In addition to their metabolic effects, PPARs/RXRs heterodi-
merize with various receptors, and these heterodimers regulate 
the transcription of genes involved in allergic inflammation 
and airway remodeling.
7 A notable finding in our study was that 
the SNP PPARG+82466C>T was associated with aspirin intoler-
ance. There were more subjects homozygous for the rare 
PPARG+82466C>T allele with AIA than with ATA in the reces-
sive model (Table 3). In the haplotype analysis, there were sig-
nificantly fewer subjects with ht1 in the AIA group than in the 
ATA group. Based on linear regression analysis, the decline in 
FEV1 after aspirin challenge in asthmatics homozygous for the 
rare +82466C>T allele was 2.5 times that in asthmatics with the 
common allele. In the haplotype analysis, the decline in FEV1 
after aspirin provocation was greater in asthmatics without the 
ht1 haplotype than in those with the haplotype. These results 
suggest that a rare PPARG+82466C>T allele and haplotype 1 are 
predisposing factors for aspirin intolerance in asthmatics.
Some eicosanoids activate PPARG; these include 13-hy-
droxyoctadecadienoic acid,
27 15-hydroxyeicosatetraenoic acid 
(15-HETE), and 15-deoxy-12,14 prostaglandinJ2 (15d-PGJ 2),
28 
a prostaglandin D2 metabolite. The accumulation of 15-HETE 
after aspirin-stimulation of peripheral leukocytes from patients 
with AIA may activate PPARG to modulate airway inflamma-
tion.
29 As metabolites of the arachidonate pathway, such as 15-
HETE and 15d-PGJ 2, regulate transcription and endogenous 
ligands for the PPARG gene, changes in these mediators in AIA 
may be responsible for the change in the amount of PPAR-r in 
the target organ of aspirin hypersensitivity. Therefore, altered 
synthesis of 15-HETE and 15d-PGJ 2 in AIA may activate 
PPARG differently from the activation in ATA. In addition, the 
PPARG agonist rosiglitazone upregulates both the mRNA ex-
pression of two lipoxygenase enzymes (platelet-type 12-lipoxy-
genase and 15-lipoxygenase) and the secretion of their eico-
sanoid products, 12- and 15-HETE. The rosiglitazone-induced 
increase in PPARG mRNA expression is blocked entirely by the 
lipoxygenase (LO) inhibitor baicalein and is restored by the ad-
dition of exogenous 12-HETE.
30 In the process of lipoxin forma-
tion, aspirin acetylation does not totally inhibit the catalysis of 
COX-2, and this can affect the production of 12-HETE, 15-
HETE, and 13-HODE. Previously, we observed that the alleles 
of the ALOX5 and ALOX5AP promoters cannot be considered 
prominent risk factors for the development of AIA. However, a 
genetic variant involving a tandem repeat (GGGCGG; Sp1-
binding motif) in the ALOX5 promoter is associated with the 
severity of airway hyper-responsiveness in AIA patients.
31 
Therefore, genetic polymorphism of the rare PPARG+82466C>T 
allele may contribute to the development of aspirin intolerance 
via a functional change in the gene, such as an altered response 
to the LO products or altered induction of the two LO enzymes. 
The molecular mechanism by which the rare PPARG+82466C>T 
allele, which does not change the encoded protein, modulates 
the phenotype is even less clear. It is possible that these variants 
are in linkage disequilibrium with other functional variants, al-
though the PPARG locus has been the focus of intense scrutiny 
as a candidate for diabetes and related traits, and no such vari-
ant has been found.
In summary, we genotyped two SNPs in the PPARG gene, 
+34C>G (Pro12Ala) and +82466C>T (His449His), and exam-
ined the association of each with the development of aspirin 
intolerance in asthmatics. Association analysis showed that 
PPARG+82466C>T and PPARG haplotypes were associated 
with the development of aspirin intolerance. Therefore, the 
+82466C>T polymorphism in the coding region of the PPARG 
gene may confer aspirin hypersensitivity via the regulation of 
gene expression. This information may be useful in the devel-
opment of new strategies for the diagnosis and control of aspi-
rin intolerance. Further studies are required to define the mo-
lecular mechanisms by which common variation at the PPARG 
locus modulates aspirin hypersensitivity, and to determine 
whether this suggests treatment strategies in asthmatics with 
different PPARG genotypes.
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